BRPI0814256A2 - Inibidores de tetrahidropiranocromeno gama secretase - Google Patents
Inibidores de tetrahidropiranocromeno gama secretaseInfo
- Publication number
- BRPI0814256A2 BRPI0814256A2 BRPI0814256-4A2A BRPI0814256A BRPI0814256A2 BR PI0814256 A2 BRPI0814256 A2 BR PI0814256A2 BR PI0814256 A BRPI0814256 A BR PI0814256A BR PI0814256 A2 BRPI0814256 A2 BR PI0814256A2
- Authority
- BR
- Brazil
- Prior art keywords
- tetrahydropyrochyromene
- secretase
- inhibitors
- range
- range inhibitors
- Prior art date
Links
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94803307P | 2007-07-05 | 2007-07-05 | |
| PCT/US2008/008192 WO2009008980A2 (en) | 2007-07-05 | 2008-07-01 | Tetrahydropyranochromene gamma secretase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0814256A2 true BRPI0814256A2 (pt) | 2015-02-03 |
| BRPI0814256A8 BRPI0814256A8 (pt) | 2016-02-10 |
Family
ID=39830164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0814256A BRPI0814256A8 (pt) | 2007-07-05 | 2008-07-01 | Inibidores de tetrahidropiranocromeno gama secretase |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8664411B2 (pt) |
| EP (1) | EP2435416B1 (pt) |
| JP (1) | JP5240871B2 (pt) |
| KR (1) | KR20100044197A (pt) |
| CN (1) | CN101754960A (pt) |
| AR (1) | AR067445A1 (pt) |
| AU (1) | AU2008275735B2 (pt) |
| BR (1) | BRPI0814256A8 (pt) |
| CA (1) | CA2691542A1 (pt) |
| CL (1) | CL2008001960A1 (pt) |
| CO (1) | CO6270309A2 (pt) |
| EC (1) | ECSP109845A (pt) |
| PE (1) | PE20090435A1 (pt) |
| RU (1) | RU2483061C2 (pt) |
| TW (1) | TW200908959A (pt) |
| WO (1) | WO2009008980A2 (pt) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008009414A (es) | 2006-01-20 | 2008-10-01 | Schering Corp | Arilsulfonas carbociclicas y heterociclicas como inhibidores de gamma secretasa. |
| CA2693216A1 (en) | 2007-07-17 | 2009-01-22 | Schering Corporation | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors |
| MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| WO2012040444A2 (en) * | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Treatment of patients with incipient alzheimer's disease |
| EP2693880A1 (en) * | 2011-04-04 | 2014-02-12 | Merck Sharp & Dohme Corp. | Gamma secretase inhibitors |
| US9226927B2 (en) * | 2011-09-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Gamma secretase inhibitors |
| EP2925313A4 (en) * | 2012-11-29 | 2016-05-11 | Merck Sharp & Dohme | SPIROCYCLIC SULPHONES AS GAMMA SECRETASE INHIBITORS |
| AU2013366668B2 (en) * | 2012-12-20 | 2017-07-20 | Janssen Pharmaceutica Nv | Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators |
| AU2014206834B2 (en) | 2013-01-17 | 2017-06-22 | Janssen Pharmaceutica Nv | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| EA201991128A1 (ru) * | 2016-11-09 | 2019-10-31 | ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ | |
| EP3634978A1 (en) | 2017-06-07 | 2020-04-15 | Adrx, Inc. | Tau aggregation inhibitors |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| EP3668886A2 (en) | 2017-08-18 | 2020-06-24 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01008606A (es) | 1999-02-26 | 2003-05-05 | Merck & Co Inc | Compuestos de sulfonamida novedosos y uso de los mismos. |
| FR2827590B1 (fr) * | 2001-07-18 | 2003-10-24 | Atuser | Transbordeur de liquides alimentaires usages |
| GB0108591D0 (en) * | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
| CN1304390C (zh) * | 2001-08-03 | 2007-03-14 | 先灵公司 | 新颖的γ—分泌酶抑制剂 |
| RU2202370C1 (ru) * | 2001-12-26 | 2003-04-20 | Эпштейн Олег Ильич | Нейропсихотропное лекарственное средство |
| GB0222833D0 (en) | 2002-10-02 | 2002-11-06 | Syngenta Ltd | Chemical process |
| GB0223039D0 (en) * | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| KR20060013404A (ko) * | 2003-05-16 | 2006-02-09 | 머크 샤프 앤드 돔 리미티드 | γ-세크레타제 억제용 사이클릭 설폰아미드 |
| GB0317491D0 (en) * | 2003-07-25 | 2003-08-27 | Novartis Ag | Organic compounds |
| DE102005062098A1 (de) * | 2005-12-22 | 2007-06-28 | Merck Patent Gmbh | Oxaphenanthren-Derivate |
| MX2008009414A (es) * | 2006-01-20 | 2008-10-01 | Schering Corp | Arilsulfonas carbociclicas y heterociclicas como inhibidores de gamma secretasa. |
| TW200813054A (en) * | 2006-06-02 | 2008-03-16 | Elan Pharm Inc | Fused, tricyclic sulfonamide inhibitors of gamma secretase |
| US8673900B2 (en) | 2008-11-13 | 2014-03-18 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
-
2008
- 2008-07-01 CN CN200880023464A patent/CN101754960A/zh active Pending
- 2008-07-01 AU AU2008275735A patent/AU2008275735B2/en not_active Ceased
- 2008-07-01 WO PCT/US2008/008192 patent/WO2009008980A2/en not_active Ceased
- 2008-07-01 CA CA002691542A patent/CA2691542A1/en not_active Abandoned
- 2008-07-01 KR KR1020107002496A patent/KR20100044197A/ko not_active Withdrawn
- 2008-07-01 BR BRPI0814256A patent/BRPI0814256A8/pt not_active IP Right Cessation
- 2008-07-01 EP EP08768856.0A patent/EP2435416B1/en active Active
- 2008-07-01 JP JP2010514862A patent/JP5240871B2/ja not_active Expired - Fee Related
- 2008-07-01 RU RU2010103716/04A patent/RU2483061C2/ru not_active IP Right Cessation
- 2008-07-01 US US12/665,580 patent/US8664411B2/en active Active
- 2008-07-02 CL CL2008001960A patent/CL2008001960A1/es unknown
- 2008-07-02 AR ARP080102867A patent/AR067445A1/es not_active Application Discontinuation
- 2008-07-02 TW TW097124900A patent/TW200908959A/zh unknown
- 2008-07-02 PE PE2008001121A patent/PE20090435A1/es not_active Application Discontinuation
-
2009
- 2009-12-30 CO CO09149364A patent/CO6270309A2/es not_active Application Discontinuation
-
2010
- 2010-01-05 EC EC2010009845A patent/ECSP109845A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8664411B2 (en) | 2014-03-04 |
| RU2010103716A (ru) | 2011-08-10 |
| EP2435416B1 (en) | 2016-03-30 |
| WO2009008980A2 (en) | 2009-01-15 |
| RU2483061C2 (ru) | 2013-05-27 |
| ECSP109845A (es) | 2010-02-26 |
| CO6270309A2 (es) | 2011-04-20 |
| CA2691542A1 (en) | 2009-01-15 |
| CL2008001960A1 (es) | 2009-11-27 |
| WO2009008980A3 (en) | 2009-03-19 |
| AU2008275735B2 (en) | 2014-03-27 |
| AR067445A1 (es) | 2009-10-14 |
| AU2008275735A1 (en) | 2009-01-15 |
| KR20100044197A (ko) | 2010-04-29 |
| PE20090435A1 (es) | 2009-04-18 |
| US20110236400A1 (en) | 2011-09-29 |
| AU2008275735A2 (en) | 2010-02-11 |
| CN101754960A (zh) | 2010-06-23 |
| JP2010532359A (ja) | 2010-10-07 |
| BRPI0814256A8 (pt) | 2016-02-10 |
| EP2435416A2 (en) | 2012-04-04 |
| JP5240871B2 (ja) | 2013-07-17 |
| TW200908959A (en) | 2009-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR20C1031I2 (fr) | Inhibiteurs de beta-lactamase | |
| BRPI0815135A2 (pt) | Derivados de azepina como inibidores de gama secretase. | |
| CY2017016I1 (el) | Αναστολεις πρωτεασωματος | |
| BRPI0812170A2 (pt) | Moduladores de gama secretase | |
| CR10831A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
| EP2305306A4 (en) | NEURO INVASION INHIBITOR | |
| BRPI0810365A2 (pt) | Inibidores de mlc-1 de indol 7-substituído | |
| BRPI0820544A2 (pt) | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase | |
| BRPI0810832A2 (pt) | Ferramenta de nível | |
| DK2041138T3 (da) | Pyrroltriazinkinase-inhibitorer | |
| BRPI1011129A2 (pt) | métodos e compostos inibidores de janus cinase | |
| DK2024375T3 (da) | Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere | |
| BRPI0918846A2 (pt) | inibidores de cinase heterocíclica | |
| BRPI0719499A2 (pt) | Composições de poliolefina | |
| EP2046887A4 (en) | Light-Crosslinkable Polyolefin Compositions | |
| EP2192838A4 (en) | HETEROCYCLIC NEKROPTOSIS HEMMER | |
| BRPI0918564A2 (pt) | inibidores | |
| CR10879A (es) | Cyclized derivatives as eg-5 inhibitors | |
| BRPI0720547A2 (pt) | Inibidores de metaloprotease derivada de heterocíclico | |
| BRPI0622049A2 (pt) | Estimativa de estado dinâmico | |
| DK2066662T3 (da) | Serinhydrolaseinhibitorer | |
| BRPI0716198A2 (pt) | Pirrolo-isoquinolinas como inibidores de cinase | |
| BRPI0922728A2 (pt) | combinação de herbicida-antídoto | |
| BRPI0806542A2 (pt) | Derivados de sulfonamida como inibidores de quimase | |
| EP2065439A4 (en) | polyolefin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |